

Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Joe Fraumeni, founder of molecular epidemiology, dies at 93
“It’s hard to imagine a world without the presence of this gentle scientific giant.” - The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions” - Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise
- Dana-Farber names its under-construction freestanding hospital: the Lavine Bekenstein Cancer Hospital
- To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements
- FDA advisory panel recommends first-of-its-kind mRNA flu vaccine for older adults











